Debate on Use of SSRIs in Pregnancy Shifting, Experts Say

For pregnant women with major depressive disorder (MDD), using selective serotonin reuptake inhibitors (SSRIs) appears to pose little risk of serious adverse outcomes for the baby, according to researchers from the Developing Brain Institute at Children's National Hospital in Washington, D.C. This shift in perspective comes in the wake of past fears, rooted in the thalidomide tragedy, which led to thousands of birth defects.

The focus has now moved towards addressing MDD to maintain maternal health. Experts argue that advising pregnant women to stop SSRIs disregards the impact of the underlying condition on maternal-fetal health and increases risks such as depression relapse, complications for the mother, and loss of function. In the U.S., around 5% to 6% of pregnant women take SSRIs, primarily for MDD, which affects about 12% of pregnant women.

The prevalence of maternal and fetal complications linked to psychiatric disorders is high. Studies show that discontinuation of SSRIs during pregnancy leads to relapse in a significant number of cases and can increase the risk of psychiatric emergencies. While some studies suggest potential links to autism or ADHD, these associations fade when confounding factors are considered.

Despite the controversy surrounding the safety of SSRIs in pregnancy, the consensus leans towards continuing treatment for severe depression, as the benefits often outweigh the risks. Experts recommend structured decision-making processes and visual aids to help patients understand the risks and benefits.